value of usual gait speed in well‐functioning older people ‐ Results from the health, aging and body composition study. J Am Geriatr Soc. 2005; 53(10):1675–1680. doi:10.1111/j.1532‐5415.2005.53501.x33 33. Cesari M, Kritchevsky SB, Newman AB, et al. Added value of physical performance measures in predicting adverse health‐related events: results from the Health, Aging And Body Composition Study. J Am Geriatr Soc. 2009; 57(2):251–259. doi:10.1111/j.1532‐5415.2008.02126.x
34 34. Studenski S, Perera S, Patel K, et al. Gait speed and survival in older adults. JAMA ‐ J Am Med Assoc. 2011; 305(1):50–58. doi:10.1001/jama.2010.1923
35 35. Mohile SG, Dale W, Somerfield MR, et al. Practical Assessment and Management of Vulnerabilities in Older Patients Receiving Chemotherapy: ASCO Guideline for Geriatric Oncology. J Clin Oncol. 2018; 36(22):2326–2347. doi:10.1200/JCO.2018.78.8687
36 36. Klepin HD, Geiger AM, Tooze JA, et al. Geriatric assessment predicts survival for older adults receiving induction chemotherapy for acute myelogenous leukemia. Blood. 2013; 121(21):4287–4294. doi:10.1182/blood‐2012‐12‐471680
37 37. Extermann M, Aapro M, Bernabei R, et al. Use of comprehensive geriatric assessment in older cancer patients: Recommendations from the task force on CGA of the International Society of Geriatric Oncology (SIOG). Crit Rev Oncol Hematol. 2005; 55(3):241–252. doi:10.1016/j.critrevonc.2005.06.003
38 38. Repetto L, Fratino L, Audisio RA, et al. Comprehensive Geriatric Assessment Adds Information to Eastern Cooperative Oncology Group Performance Status in Elderly Cancer Patients: An Italian Group for Geriatric Oncology Study. J Clin Oncol. 2002; 20(2):494–502. doi:10.1200/JCO.2002.20.2.494
39 39. Extermann M, Overcash J, Lyman GH, Parr J, Balducci L. Comorbidity and functional status are independent in older cancer patients. J Clin Oncol. 1998; 16(4):1582–1587. doi:10.1200/JCO.1998.16.4.1582
40 40. Hurria A, Togawa K, Mohile SG, et al. Predicting Chemotherapy Toxicity in Older Adults With Cancer: A Prospective Multicenter Study. J Clin Oncol. 29:3457–3465. doi:10.1200/JCO.2011.34.7625
41 41. Haase D, Germing U, Schanz J, et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood. 2007; 110(13):4385–4395. doi:10.1182/blood‐2007‐03‐082404
42 42. Heaney ML, Golde DW. Myelodysplasia. N Engl J Med. 1999; 340(21):1649–1660. doi:10.1056/NEJM199905273402107
43 43. Bernasconi P, Alessandrino EP, Boni M, et al. Karyotype in myelodysplastic syndromes: relations to morphology, clinical evolution, and survival. Am J Hematol. 1994; 46(4):270–277. doi:10.1002/ajh.2830460404
44 44. Hong M, He G. The 2016 revision to the World Health Organization classification of myelodysplastic syndromes. J Transl Intern Med. 2017; 5(3):139–143. doi:10.1515/jtim‐2017‐0002
45 45. Genovese G, Kähler AK, Handsaker RE, et al. Clonal hematopoiesis and blood‐cancer risk inferred from blood DNA sequence. N Engl J Med. 2014; 371(26):2477–2487. doi:10.1056/NEJMoa1409405
46 46. Sanz‐De Pedro M, Wang W, Kanagal‐Shamanna R, Khoury JD. Myelodysplastic Syndromes: Laboratory Workup in the Context of New Concepts and Classification Criteria. Curr Hematol Malig Rep. 2018; 13(6):467–476. doi:10.1007/s11899‐018‐0483‐5
47 47. Cazzola M, Della Porta MG, Malcovati L. The genetic basis of myelodysplasia and its clinical relevance. Blood. 2013; 122(25):4021–4034. doi:10.1182/blood‐2013‐09‐381665
48 48. Tefferi A, Pardanani A, Lim KH, et al. TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis. Leukemia. 2009; 23(5):905–911. doi:10.1038/leu.2009.47
49 49. Delhommeau F, Dupont S, Della Valle V, et al. Mutation in TET2 in myeloid cancers. N Engl J Med. 2009; 360(22):2289–2301. doi:10.1056/NEJMoa0810069
50 50. Abdel‐Wahab O, Mullally A, Hedvat C, et al. Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood. 2009; 114(1):144–147. doi:10.1182/blood‐2009‐03‐210039
51 51. Itzykson R, Kosmider O, Cluzeau T, et al. Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias. Leukemia. 2011; 25(7):1147–1152. doi:10.1038/leu.2011.71
52 52. Malcovati L, Karimi M, Papaemmanuil E, et al. SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts. Blood. 2015; 126(2):233–241. doi:10.1182/blood‐2015‐03‐633537
53 53. Patnaik MM, Hanson CA, Sulai NH, et al. Prognostic irrelevance of ring sideroblast percentage in World Health Organization‐defined myelodysplastic syndromes without excess blasts. Blood. 2012; 119(24):5674–5677. doi:10.1182/blood‐2012‐03‐415356
54 54. Bejar R, Lord A, Stevenson K, et al. TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients. Blood. 2014; 124(17):2705–2712. doi:10.1182/blood‐2014‐06‐582809
55 55. Valent P, Horny H, Bennett JM, et al. Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes : Consensus statements and report from a working conference. 2007; 31:727–736. doi:10.1016/j.leukres.2006.11.009
56 56. Harris NL, Jaffe ES, Diebold J, et al. World health organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the clinical advisory committee meeting ‐ Airlie house, Virginia, November 1997. J Clin Oncol. 1999; 17(12):3835–3849. doi:10.1200/JCO.1999.17.12.3835
57 57. Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016; 127(20):2391–2405. doi:10.1182/blood‐2016‐03‐643544
58 58. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: Rationale and important changes. Blood. 2009; 114(5):937–951. doi:10.1182/blood‐2009‐03‐209262
59 59. Greenberg PL, Stone RM, Al‐Kali A, et al. Myelodysplastic syndromes, version 2.2017: Clinical practice guidelines in oncology. JNCCN J Natl Compr Cancer Netw. 2017; 15(1):60–87. doi:10.6004/jnccn.2017.0007
60 60. Montalban‐Bravo G, Garcia‐Manero G. Myelodysplastic syndromes: 2018 update on diagnosis, risk‐stratification and management. Am J Hematol. 2018; 93(1):129–147. doi:10.1002/ajh.24930
61 61. Kantarjian H, O’Brien S, Ravandi F, et al. Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System. Cancer. 2008; 113(6):1351–1361. doi:10.1002/cncr.23697
62 62. Malcovati L, Germing U, Kuendgen A, et al. Time‐Dependent Prognostic Scoring System for Predicting Survival and Leukemic Evolution in Myelodysplastic Syndromes. J Clin Oncol. 2007; 25(23):3503–3510. doi:10.1200/JCO.2006.08.5696
63 63. Fega KR, Abel GA, Motyckova G, et al. Non‐hematologic predictors of mortality improve the prognostic value of the international prognostic scoring system for MDS in older adults. J Geriatr Oncol. 2015; 6(4):288–298. doi:10.1016/j.jgo.2015.05.003
64 64. Steensma DP. Hematopoietic growth factors in myelodysplastic syndromes. Semin Oncol. 2011; 38(5):635–647. doi:10.1053/j.seminoncol.2011.04.014
65 65. Greenberg PL, Sun Z, Miller KB, et al. Treatment of myelodysplastic syndrome patients with erythropoietin
